Analysts’ Viewpoint on Digital Dose Inhalers Market Scenario
Digital dose inhalers, which feature sensors and wireless connectivity, help address the need for optimized adherence to maintenance medication in patients with respiratory diseases. Physicians tend to prescribe these products for respiratory diseases such as COPD and asthma. This is driving the digital dose inhalers market. Investment in technologically advanced products, such as smart inhalers, is expected to enable manufacturers to achieve high ROI. However, low awareness about digital dose inhalers among the population could hamper sales. Nevertheless, introduction of reimbursement plans to cushion healthcare expenditure is projected to lead to positive sentiment among patients toward effective treatment.
Digital dose inhalers are advanced, smart devices intended to treat and manage drug delivery for various respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Digital dose inhalers are used to provide a simple, accurate, and reliable dose counter, which enables patients to track adherence to their therapy. Increase in patient population, adoption of novel technologies, and surge in research & development in developed and developing countries are driving the global digital dose inhalers market. Furthermore, rise in prevalence of respiratory diseases such as asthma and COPD (chronic obstructive pulmonary disorder) across the globe and increase in geriatric population are projected to drive the global digital dose inhalers market in the next few years. Thus, demand for digital inhalers for chronic obstructive pulmonary disease is anticipated to increase substantially across the globe. Introduction of data integration with EHR (electronic health records) or EMR (electronic medical records) is a major trend in the global digital dose inhalers market. However, management of chronic airway diseases is 10% medication and 90% education. Inability of patients to effectively use inhaler devices can be largely ascribed to deficiencies in clinicians’ knowledge of inhaler techniques. Thus, lack of knowledge, awareness, and training required to instruct patients in proper usage of digital inhalers is restraining the global digital dose inhalers market.
Emerging economies such as India, China, Brazil, and Mexico offer significant opportunities in the global digital dose inhalers market. Presence of large geriatric population; government initiatives to improve healthcare sector; rise in research & development activities; and increase in pollution, allergens, and occupational dust are factors driving the market in these countries. The highest rate of hospitalization in India is for cardiac and respiratory problems, and for asthma in Bangladesh. In 2020, the WHO estimated geriatric population of around 1,000 million, with 700 million of them living in developing countries. This offers lucrative opportunities for market players.
The outbreak of COVID-19 has had a positive effect on the global digital dose inhalers market. Governments of affected countries gave instructions for the postponement of non-essential surgeries and patient visits. Respiratory support devices such as atomizers, life-support machines, oxygen generators, and monitors are among the majorly used medical devices in primary clinical treatment. Hence, COVID-19 has led to a surge in demand for these products. Furthermore, worsening of the pandemic situation affected the supply and demand gap and increased the demand for digital dose inhaler devices. Patients with asthma are at a higher risk of contracting COVID-19. As the virus continues to spread, hospitals are increasingly using metered dose inhaler. COVID-19 is sparking fear of medication shortage and panic buying, which could lead to a shortage of critical inhalers. Therefore, increase in panic buying, high risk of COVID-19 among patients with respiratory diseases, and high demand and supply gap are driving the global digital dose inhalers market.
In terms of product, the metered dose inhalers segment accounted for major share of the global digital dose inhalers market in 2021. This can be ascribed to the rise in penetration and product launch of metered dose inhalers; and increase in awareness about these products among patients. According to NCBI, the inherent multi-dose nature of MDIs makes them more affordable than most competing inhalation delivery systems. Thu, metered dose inhalers are considered highly popular inhalers to treat local respiratory diseases such as asthma and COPD.
Increase in regulatory approvals is driving the metered dose inhalers segment. For instance, in December 2018, AstraZeneca received approval from the European Commission (EC) for Bevespi Aerosphere, which is used in a pressurized metered dose inhaler (pMDI) indicated as maintenance dual bronchodilator treatment in adult patients with COPD. This approval enabled the company to add a technologically advanced product to its existing product offerings for patients in Europe.
In terms of application, the asthma segment accounted for significant share of the global digital dose inhalers market in 2021. This can be ascribed to high prevalence and product launches. According to the WHO, asthma was a major non-communicable disease in 2019. Asthma affected an estimated 262 million people and caused 455,000 deaths in 2019. According to the Asthma and Allergy Foundation of America, more than 26 million people in the U.S. suffer from asthma. Incidence of asthma has been increasing since the early 1980s in all ages, sexes, and racial groups.
Rise in launch of digital inhalers for asthma is driving the asthma segment. For instance, in January 2017, Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) approved two of its products for adolescent and adult patients with asthma. These products, i.e. AirDuo RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAir RespiClick (fluticasone propionate inhalation powder), include medication delivered via Teva’s RespiClick breath-activated, multi-dose dry powder inhaler (mDPI), which is also used with other approved medicines from Teva’s respiratory inhaler product portfolio.
North America dominated the global digital dose inhalers market in 2021. The region’s dominance of the global market can be ascribed to high prevalence and increase in incidence of COPD and asthma in the U.S. and Canada; well-established healthcare infrastructure; and high risk of lifestyle-related diseases. Furthermore, increase in trend of smoking in North America is propelling the risk of asthma. Smoking is directly responsible for around 90% of lung cancer deaths and nearly 80% of deaths caused by chronic obstructive pulmonary disease (COPD) including emphysema and chronic bronchitis. Additionally, robust product pipeline of key players is projected to drive the global digital dose inhalers market in North America.
Asia Pacific is anticipated to be the fastest growing market for digital dose inhalers during the forecast period. China dominated the digital dose inhalers market in the region in 2021. The digital dose inhalers market in India is likely to grow at a high CAGR during the forecast period. According to Lung India, a recent Indian study on Epidemiology of Asthma, Respiratory Symptoms and Chronic Bronchitis (INSEARCH) conducted on 85,105 men and 84,470 women from 12 urban and 11 rural sites in India, the rate of prevalence of asthma in India stands at 2.05% among individuals aged over 15 years, with a burden of around 18 million asthma patients across the country.
The digital dose inhalers market in Latin America and Middle East & Africa is likely to grow at a decent CAGR owing to the increase in respiratory disease patient pool and focus of manufacturers on the development of novel products.
This report includes vital information about the key players operating in the global digital dose inhalers market. Digital dose inhaler companies are focusing on strategies such as new product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market. Novartis AG, AstraZeneca, Glenmark, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., 3M, Sensirion AG Switzerland, AptarGroup, Inc., Cipla, Inc., and H&T Presspart Manufacturing Ltd. are the prominent players operating in the global digital dose inhalers market.
Each of these players has been profiled in the digital dose inhalers market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 2.23 Bn |
|
Market Forecast Value in 2031 |
More than US$ 7.22 Bn |
|
Compound Annual Growth Rate (CAGR) |
12.5% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global digital dose inhalers market was valued at US$ 2.23 Bn in 2021.
The global digital dose inhalers market is projected to reach more than US$ 7.22 Bn by 2031.
The global digital dose inhalers market is anticipated to grow at a CAGR of 12.5% from 2022 to 2031.
Increase in incidence of COPD and asthma is driving the global digital dose inhalers market
North America is expected to account for major share of the global digital dose inhalers market during the forecast period
Novartis AG, AstraZeneca, Glenmark, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., 3M, Sensirion AG Switzerland, AptarGroup, Inc., Cipla, Inc., and H&T Presspart Manufacturing Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Digital Dose Inhalers Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Digital Dose Inhalers Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Technological Advancements
5.2. Key Industry Events (Mergers, Acquisitions, Product Launch , etc.)
5.3. Epidemiology of Respiratory Diseases, such as Asthma, COPD (Chronic Obstructive Pulmonary Disease),etc.
6. Global Digital Dose Inhalers Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Metered Dose Inhalers
6.3.2. Dry Powder Inhalers
6.4. Market Attractiveness Analysis, by Product
7. Global Digital Dose Inhalers Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Asthma
7.3.2. COPD (chronic obstructive pulmonary disease)
7.3.3. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Digital Dose Inhalers Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Digital Dose Inhalers Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product, 2017–2031
9.2.1. Metered Dose Inhalers
9.2.2. Dry Powder Inhalers
9.3. Market Value Forecast, by Application, 2017–2031
9.3.1. Asthma
9.3.2. COPD (chronic obstructive pulmonary disease)
9.3.3. Others
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product
9.5.2. By Application
9.5.3. By Country
10. Europe Digital Dose Inhalers Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017–2031
10.2.1. Metered Dose Inhalers
10.2.2. Dry Powder Inhalers
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Asthma
10.3.2. COPD (chronic obstructive pulmonary disease)
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product
10.5.2. By Application
10.5.3. By Country/Sub-region
11. Asia Pacific Digital Dose Inhalers Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Metered Dose Inhalers
11.2.2. Dry Powder Inhalers
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Asthma
11.3.2. COPD (chronic obstructive pulmonary disease)
11.3.3. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product
11.5.2. By Application
11.5.3. By Country/Sub-region
12. Latin America Digital Dose Inhalers Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Metered Dose Inhalers
12.2.2. Dry Powder Inhalers
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Asthma
12.3.2. COPD (chronic obstructive pulmonary disease)
12.3.3. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product
12.5.2. By Application
12.5.3. By Country/Sub-region
13. Middle East & Africa Digital Dose Inhalers Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Metered Dose Inhalers
13.2.2. Dry Powder Inhalers
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Asthma
13.3.2. COPD (chronic obstructive pulmonary disease)
13.3.3. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Israel
13.4.4. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product
13.5.2. By Application
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share/Position Analysis, by Company, 2021
14.3. Company Profiles
14.3.1. Novartis AG
14.3.1.1. Company Overview
14.3.1.2. Company Financials
14.3.1.3. Growth Strategies
14.3.1.4. SWOT Analysis
14.3.2. AstraZeneca
14.3.2.1. Company Overview
14.3.2.2. Company Financials
14.3.2.3. Growth Strategies
14.3.2.4. SWOT Analysis
14.3.3. Glenmark
14.3.3.1. Company Overview
14.3.3.2. Company Financials
14.3.3.3. Growth Strategies
14.3.3.4. SWOT Analysis
14.3.4. GlaxoSmithKline plc
14.3.4.1. Company Overview
14.3.4.2. Company Financials
14.3.4.3. Growth Strategies
14.3.4.4. SWOT Analysis
14.3.5. Teva Pharmaceutical Industries Ltd.
14.3.5.1. Company Overview
14.3.5.2. Company Financials
14.3.5.3. Growth Strategies
14.3.5.4. SWOT Analysis
14.3.6. 3M
14.3.6.1. Company Overview
14.3.6.2. Company Financials
14.3.6.3. Growth Strategies
14.3.6.4. SWOT Analysis
14.3.7. Sensirion AG Switzerland
14.3.7.1. Company Overview
14.3.7.2. Company Financials
14.3.7.3. Growth Strategies
14.3.7.4. SWOT Analysis
14.3.8. AptarGroup, Inc.
14.3.8.1. Company Overview
14.3.8.2. Company Financials
14.3.8.3. Growth Strategies
14.3.8.4. SWOT Analysis
14.3.9. Cipla, Inc.
14.3.9.1. Company Overview
14.3.9.2. Company Financials
14.3.9.3. Growth Strategies
14.3.9.4. SWOT Analysis
14.3.10. H&T Presspart Manufacturing Ltd.
14.3.10.1. Company Overview
14.3.10.2. Company Financials
14.3.10.3. Growth Strategies
14.3.10.4. SWOT Analysis
*Note: Financial details for companies that do not report this information in public domain might not be captured
List of Tables
Table 01: Epidemiology of Respiratory Diseases, such as Asthma, COPD (Chronic Obstructive Pulmonary Disease), etc.
Table 02: Epidemiology of Respiratory Diseases, such as Asthma, COPD (Chronic Obstructive Pulmonary Disease), etc.
Table 03: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 04: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 05: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 08: North America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 11: Europe Digital Dose Inhalers Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Asia Pacific Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: Asia Pacific Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 14: Asia Pacific Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 15: Latin America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Latin America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 17: Latin America Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Middle East & Africa Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 19: Middle East & Africa Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Product, 2017–2031
Table 20: Middle East & Africa Digital Dose Inhalers Market Value (US$ Mn) Forecast, by Application, 2017–2031
List of Figures
Figure 01: Global Digital Dose Inhalers Market Size (US$ Mn) and Distribution, by Region, 2021 and 2031
Figure 02: Global Digital Dose Inhalers Market Revenue (US$ Mn), by Product, 2021
Figure 03: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 04: Global Digital Dose Inhalers Market Value Share (%), by Product, 2021 and 2031
Figure 05: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Metered Dose Inhalers, 2017–2031
Figure 06: Global Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dry Powder Inhalers, 2017–2031
Figure 07: Global Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031
Figure 08: Global Digital Dose Inhalers Market Value Share, by Application, 2021 and 2031
Figure 09: Global Digital Dose Inhalers Market Attractiveness Analysis, by Application, 2017–2031
Figure 10: Global Digital Dose Inhalers Market Value (US$ Mn) and Y-o-Y Growth, by Asthma, 2017–2031
Figure 11: Global Digital Dose Inhalers Market Value (US$ Mn) and Y-o-Y Growth, by COPD (chronic obstructive pulmonary disease), 2017–2031
Figure 12: Global Digital Dose Inhalers Market Value (US$ Mn) and Y-o-Y Growth, by Others, 2017–2031
Figure 13: Global Digital Dose Inhalers Market Value Share, by Region, 2021 and 2031
Figure 14: Global Digital Dose Inhalers Market Attractiveness Analysis, by Region, 2017–2031
Figure 15: North America Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 16: North America Digital Dose Inhalers Market Value Share (%), by Country, 2021 and 2031
Figure 17: North America Digital Dose Inhalers Market Attractiveness Analysis, by Country, 2017–2031
Figure 18: North America Digital Dose Inhalers Market Value Share, by Product, 2021 and 2031
Figure 19: North America Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031
Figure 20: North America Digital Dose Inhalers Market Value Share Analysis, by Application, 2021 and 2031
Figure 21: North America Digital Dose Inhalers Market Attractiveness Analysis, by Application, 2017–2031
Figure 22: Europe Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 23: Europe Digital Dose Inhalers Market Value Share (%), by Country / Sub-region, 2021 and 2031
Figure 24: Europe Digital Dose Inhalers Market Attractiveness Analysis, by Country / Sub-region, 2017–2031
Figure 25: Europe Digital Dose Inhalers Market Value Share, by Product, 2021 and 2031
Figure 26: Europe Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031
Figure 27: Europe Digital Dose Inhalers Market Value Share Analysis, by Application, 2021 and 2031
Figure 28: Europe Digital Dose Inhalers Market Attractiveness Analysis, by Application, 2017–2031
Figure 29: Asia Pacific Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 30: Asia Pacific Digital Dose Inhalers Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 31: Asia Pacific Digital Dose Inhalers Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 32: Asia Pacific Digital Dose Inhalers Market Value Share, by Product, 2021 and 2031
Figure 33: Asia Pacific Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031
Figure 34: Asia Pacific Digital Dose Inhalers Market Value Share Analysis, by Application, 2021 and 2031
Figure 35: Asia Pacific Digital Dose Inhalers Market Attractiveness Analysis, by Application, 2017–2031
Figure 36: Latin America Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 37: Latin America Digital Dose Inhalers Market Value Share (%), by Country / Sub-region, 2021 and 2031
Figure 38: Latin America Digital Dose Inhalers Market Attractiveness Analysis, by Country / Sub-region, 2017–2031
Figure 39: Latin America Digital Dose Inhalers Market Value Share, by Product, 2021 and 2031
Figure 40: Latin America Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031
Figure 41: Latin America Digital Dose Inhalers Market Value Share Analysis, by Application, 2021 and 2031
Figure 42: Latin America Digital Dose Inhalers Market Attractiveness Analysis, by Application, 2017–2031
Figure 43: Middle East & Africa Digital Dose Inhalers Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 44: Middle East & Africa Digital Dose Inhalers Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 45: Middle East & Africa Digital Dose Inhalers Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 46: Middle East & Africa Digital Dose Inhalers Market Value Share, by Product, 2021 and 2031
Figure 47: Middle East & Africa Digital Dose Inhalers Market Attractiveness Analysis, by Product, 2017–2031
Figure 48: Middle East & Africa Digital Dose Inhalers Market Value Share Analysis, by Application, 2021 and 2031
Figure 49: Middle East & Africa Digital Dose Inhalers Market Attractiveness, by Application, 2017–2031
Figure 50: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2021
Figure 51: Novartis AG R&D Intensity and Sales & Marketing Intensity - Company Level, 2017–2021
Figure 52: Novartis AG Breakdown of Net Sales (%), by Region, 2021
Figure 53: Novartis AG Breakdown of Net Sales (%), by Business Segment, 2021
Figure 54: AstraZeneca Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2021
Figure 55: AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2021
Figure 56: AstraZeneca Breakdown of Net Sales (%), by Region, 2021
Figure 57: AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2021
Figure 58: Glenmark (US$ Mn) Revenue, 2017–2021
Figure 59: Distribution of Glenmark Revenue (%), by Region, 2021
Figure 60: GlaxoSmithKline plc. Revenue (US$ Mn), 2017–2021
Figure 61: GlaxoSmithKline plc. R&D Expenses (US$ Mn), 2017–2021
Figure 62: GlaxoSmithKline plc. Breakdown of Net Sales (%), by Region, 2021
Figure 63: GlaxoSmithKline plc. Breakdown of Net Sales (%), by Business Segment, 2021
Figure 64: Teva Pharmaceutical Industries Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2021
Figure 65: Teva Pharmaceutical Industries Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016–2021
Figure 66: Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Region, 2021
Figure 67: 3M , Revenue (US$ Mn) & Y-o-Y Growth (%), 2016–2021
Figure 68: 3M , R&D Expenses (US$ Mn) & Y-o-Y Growth (%), 2016-2021
Figure 69: 3M, Breakdown of Net Sales (%), by Region, 2021
Figure 70: 3M Breakdown of Net Sales (%), by Business Segment, 2021
Figure 71: Sensirion AG Switzerland, Revenue (US$ Mn) & Y-o-Y Growth (%), 2016–2021
Figure 72: Sensirion AG Switzerland, R&D Expenses (US$ Mn), 2017-2021
Figure 73: Sensirion AG Switzerland, Breakdown of Net Sales (%), by Region, 2021
Figure 74: Sensirion AG Switzerland, Breakdown of Net Sales (%), by Business Segment, 2021
Figure 75: AptarGroup, Inc., Revenue (US$ Mn) & Y-o-Y Growth (%), 2016–2021
Figure 76: AptarGroup, Inc., R&D Expenses (US$ Mn), 2016-2021
Figure 77: AptarGroup, Inc., Breakdown of Net Sales (%), by Region, 2021
Figure 78: AptarGroup, Inc., Breakdown of Net Sales (US$ Mn), by Business Segment, 2021
Figure 79: Cipla Inc., Revenue (US$ Mn), 2017–2021
Figure 80: Cipla Inc., Breakdown of Net Sales (%), by Region, 2021
Figure 81: Cipla Inc., Breakdown of Net Sales (%), by Business Segment, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Digital Dose Inhalers Market
